TY - JOUR
T1 - Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients
T2 - a systematic review and meta-analysis
AU - Patel, Priya
AU - Robinson, Paula D.
AU - Wahib, Nora
AU - Cheung, Patrick
AU - Wong, Thomas
AU - Cabral, Sandra
AU - Parker, Arden
AU - Cohen, Marie
AU - Devine, Katie
AU - Gibson, Paul
AU - Holdsworth, Mark T.
AU - Neumann, Eloise
AU - Orsey, Andrea
AU - Phillips, Robert
AU - Spinelli, Daniela
AU - Thackray, Jennifer
AU - van de Wetering, Marianne
AU - Woods, Deborah
AU - Sung, Lillian
AU - Dupuis, L. Lee
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/11
Y1 - 2022/11
N2 - Purpose: To identify effective and safe interventions to prevent acute phase chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric patients. Methods: We conducted a systematic review of randomized trials evaluating interventions to prevent acute CINV. Outcomes assessed were complete chemotherapy-induced vomiting (CIV) control, complete chemotherapy-induced nausea (CIN) control, complete CINV control, and discontinuation of antiemetics due to adverse effects. Results: The search identified 65,172 citations; 744 were evaluated at full-text, and 295 (25 pediatric) met eligibility criteria. In patients receiving highly emetogenic chemotherapy (HEC), complete CIV (risk ratio (RR) 1.23, 95% confidence interval (CI) 1.05–1.44) and CIN (RR 1.34, 95% CI 1.10–1.62) control improved when olanzapine was added. The addition of a neurokinin-1 receptor antagonist (NK1RA) to a corticosteroid plus a serotonin-3 receptor antagonist (5HT3RA) also improved complete CIV (RR 1.11, 95% CI 1.08–1.14) and CIN (RR 1.05, 95% CI 1.01–1.08) control. Compared to granisetron/ondansetron, palonosetron provided improved complete CIV control when the 5HT3RA was given alone or when combined with dexamethasone. In patients receiving moderately emetogenic chemotherapy (MEC), dexamethasone plus a 5HT3RA improved complete CIV control compared to a 5HT3RA alone (RR 1.29, 95% CI 1.21–1.39). Only a single meta-analysis evaluating the safety outcome was possible. Conclusions: For patients receiving HEC, various antiemetic regimens improved CIV and CIN control. For patients receiving MEC, administration of a 5HT3RA plus dexamethasone improved CIV control. Analysis of antiemetic safety was constrained by lack of data.
AB - Purpose: To identify effective and safe interventions to prevent acute phase chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric patients. Methods: We conducted a systematic review of randomized trials evaluating interventions to prevent acute CINV. Outcomes assessed were complete chemotherapy-induced vomiting (CIV) control, complete chemotherapy-induced nausea (CIN) control, complete CINV control, and discontinuation of antiemetics due to adverse effects. Results: The search identified 65,172 citations; 744 were evaluated at full-text, and 295 (25 pediatric) met eligibility criteria. In patients receiving highly emetogenic chemotherapy (HEC), complete CIV (risk ratio (RR) 1.23, 95% confidence interval (CI) 1.05–1.44) and CIN (RR 1.34, 95% CI 1.10–1.62) control improved when olanzapine was added. The addition of a neurokinin-1 receptor antagonist (NK1RA) to a corticosteroid plus a serotonin-3 receptor antagonist (5HT3RA) also improved complete CIV (RR 1.11, 95% CI 1.08–1.14) and CIN (RR 1.05, 95% CI 1.01–1.08) control. Compared to granisetron/ondansetron, palonosetron provided improved complete CIV control when the 5HT3RA was given alone or when combined with dexamethasone. In patients receiving moderately emetogenic chemotherapy (MEC), dexamethasone plus a 5HT3RA improved complete CIV control compared to a 5HT3RA alone (RR 1.29, 95% CI 1.21–1.39). Only a single meta-analysis evaluating the safety outcome was possible. Conclusions: For patients receiving HEC, various antiemetic regimens improved CIV and CIN control. For patients receiving MEC, administration of a 5HT3RA plus dexamethasone improved CIV control. Analysis of antiemetic safety was constrained by lack of data.
KW - Chemotherapy
KW - Nausea
KW - Pediatrics
KW - Supportive care
KW - Vomiting
KW - Nausea/chemically induced
KW - Humans
KW - Neoplasms/drug therapy
KW - Vomiting/chemically induced
KW - Dexamethasone/therapeutic use
KW - Adult
KW - Antineoplastic Agents/adverse effects
KW - Child
KW - Antiemetics/therapeutic use
UR - https://www.scopus.com/pages/publications/85135834651
UR - https://www.mendeley.com/catalogue/97709f85-c60b-3801-b3be-4e658e5e4719/
U2 - 10.1007/s00520-022-07287-w
DO - 10.1007/s00520-022-07287-w
M3 - Review article
C2 - 35953731
AN - SCOPUS:85135834651
SN - 0941-4355
VL - 30
SP - 8855
EP - 8869
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 11
ER -